Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 2/6 |
Past Performance | 3/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Ipsen S.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €113.16 |
52 Week High | €130.70 |
52 Week Low | €99.50 |
Beta | 0.64 |
1 Month Change | 3.32% |
3 Month Change | 5.75% |
1 Year Change | 5.98% |
3 Year Change | 38.82% |
5 Year Change | 8.71% |
Change since IPO | 201.93% |
Recent News & Updates
Recent updates
Shareholder Returns
0MH6 | GB Pharmaceuticals | GB Market | |
---|---|---|---|
7D | 5.4% | 3.3% | 2.7% |
1Y | 6.0% | -3.7% | 0.3% |
Price Volatility
0MH6 volatility | |
---|---|
0MH6 Average Weekly Movement | 3.8% |
Pharmaceuticals Industry Average Movement | 8.4% |
Market Average Movement | 4.9% |
10% most volatile stocks in GB Market | 11.3% |
10% least volatile stocks in GB Market | 2.7% |
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1929 | 5,325 | David Loew | www.ipsen.com |
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial.
Ipsen S.A. Fundamentals Summary
0MH6 fundamental statistics | |
---|---|
Market cap | €9.20b |
Earnings (TTM) | €617.10m |
Revenue (TTM) | €3.31b |
14.9x
P/E Ratio2.8x
P/S RatioIs 0MH6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0MH6 income statement (TTM) | |
---|---|
Revenue | €3.31b |
Cost of Revenue | €571.20m |
Gross Profit | €2.74b |
Other Expenses | €2.12b |
Earnings | €617.10m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Jul 25, 2024
Earnings per share (EPS) | 7.47 |
Gross Margin | 82.72% |
Net Profit Margin | 18.66% |
Debt/Equity Ratio | 9.6% |
How did 0MH6 perform over the long term?
See historical performance and comparisonDividends
1.1%
Current Dividend Yield16%
Payout RatioDoes 0MH6 pay a reliable dividends?
See 0MH6 dividend history and benchmarksIpsen dividend dates | |
---|---|
Ex Dividend Date | May 30 2024 |
Dividend Pay Date | Jun 03 2024 |
Days until Ex dividend | 35 days |
Days until Dividend pay date | 39 days |
Does 0MH6 pay a reliable dividends?
See 0MH6 dividend history and benchmarks